Drugs / IDP-023
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06677710 | Jun → Dec 2026 | primary progressive multiple sclerosis, secondary progressive multiple sclerosis | Indapta Therapeutics, INC. | Suspended | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06119685 | Oct 2023 → Dec 2025 overdue | non-Hodgkin lymphoma, plasma cell myeloma | Indapta Therapeutics, INC. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-05-17 | Indapta Therapeutics, INC. | Regulatory Indapta Therapeutics Announces U.S. FDA Clearance of IND for IDP-023, an Allogeneic Natural Killer (NK) Cell Therapy for Cancer – First-in-human trial of G-NK cells in combination with monoclonal antibodies for patients with relapsed/refractory multiple myeloma or lymphoma expected to commence in second half of indapta.com ↗
Indapta Therapeutics Announces U.S. FDA Clearance of IND for IDP-023, an Allogeneic Natural Killer (NK) Cell Therapy for Cancer |
All press releases naming this drug 1 release
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDP-023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06119685 ↗ |
| Action | Deplete | “These cells may be particularly effective at targeting and killing the cells that cause the immune system to attack the nervous system in multiple sclerosis (MS).” NCT06677710 ↗ |
| Modality | Cell therapy | “off-the-shelf, allogeneic cell product made of "natural killer" cells, also called NK cells” NCT06119685 ↗ |